Related references
Note: Only part of the references are listed.
Article
Cell Biology
Elena Campello et al.
Summary: The study found that extracellular vesicles (EVs) from cells involved in COVID-19-associated coagulopathy increased in COVID-19 patients at admission and discharge, with a decrease in endothelium-derived EVs 30 days post-discharge, while platelet- and leukocyte-derived EVs further increased.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Hematology
Karina Althaus et al.
Summary: The pathophysiology of COVID-19-associated thrombosis is multifactorial, involving procoagulant platelets and alterations in various cellular processes. Studies have found that COVID-19 patients exhibit increased platelet dysfunction and apoptosis markers, suggesting a potential role of antibody-mediated procoagulant platelets in contributing to sustained thromboembolic risk in ICU COVID-19 patients.
Article
Medicine, General & Internal
Chaolin Huang et al.
Summary: This study aimed to investigate the long-term health consequences of discharged COVID-19 patients and associated risk factors, particularly disease severity. Patients with more severe illness during hospitalization showed more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, highlighting the need for targeted interventions for long-term recovery.
Article
Cell Biology
Dario Bongiovanni et al.
Summary: This study found that platelets of COVID-19 patients showed increased expression of activation markers without stimulation, and further elevated expression of P-selectin when stimulated with TRAP. However, COVID-19 platelets exhibited reduced capacity to express LAMP-3 and P-selectin upon TRAP stimulation. These findings suggest a hyperactivated platelet phenotype during SARS-CoV-2 infection, potentially contributing to the observed hypercoagulopathy in COVID-19 patients.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Shane P. Comer et al.
Summary: This study found distinct differences in routine full blood count and other clinical laboratory parameters between patients with severe and nonsevere COVID-19. It also determined that all COVID-19 patients possess hyperactive circulating platelets, suggesting abnormal platelet reactivity may contribute to hypercoagulability in COVID-19, influencing the severity of the disease and recovery path complexity.
Letter
Respiratory System
Anna Birnhuber et al.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Cell Biology
Yashuan Chao et al.
Summary: This study found that in patients with COVID-19, platelets are more responsive during the acute phase while neutrophils are less responsive, potentially associated with disease severity and cytokine levels.
Article
Medicine, Research & Experimental
Adriadne J. Bertolin et al.
Summary: In this study, platelet reactivity was significantly lower in patients with non-severe COVID-19 compared to healthy controls, despite higher levels of d-dimer, fibrinogen, and plasminogen activator inhibitor 1 (PAI-1) in the COVID-19 group. Thromboelastometry also indicated a hypercoagulable state in the COVID-19 group.
ADVANCES IN THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Chiara Agrati et al.
Summary: Severe COVID-19 cases present with blood clots and neutrophil-platelet aggregates, leading to an increased risk of cardiovascular complications and venous thrombotic events. The inflammatory storm may disrupt the interplay between platelets, endothelium, and leukocytes, contributing to COVID-19-associated coagulopathy. P-selectin is identified as a key molecule in this process and could potentially be used as a severity marker and therapeutic target for COVID-19 treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Tessa J. Barrett et al.
Summary: Platelet count, size, and maturity are associated with increased critical illness and all-cause mortality among hospitalized COVID-19 patients. SARS-CoV-2 virions enter megakaryocytes and platelets in COVID-19 patients, leading to alterations in the platelet transcriptome and activation profile. In vitro mechanistic studies show that the interaction of SARS-CoV-2 with megakaryocytes causes distinct effects on platelets compared to the coronavirus responsible for the common cold (CoV-OC43).
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Multidisciplinary Sciences
Sofie Bliddal et al.
Summary: Among non-hospitalized PCR-confirmed COVID-19 patients, one third were asymptomatic, while one third of symptomatic participants reported persistent symptoms. Risk factors for persistent symptoms included female sex and BMI.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Tessa J. Barrett et al.
Summary: The study reveals an inflammatory hypercoagulable state between platelets and endothelial cells in COVID-19, with platelet-released factors promoting endotheliopathy. S100A8, S100A9, and their protein product MRP8/14 are enriched in COVID-19 platelets and contribute significantly to poor clinical outcomes. Targeting platelet P2Y(12) appears to be a promising strategy for reducing proinflammatory platelet-endothelial interactions in COVID-19.
Article
Cardiac & Cardiovascular Systems
Paola Canzano et al.
Summary: The authors suggest that the cytokine storm in COVID-19 patients can lead to sustained cell-based activation of coagulation and altered platelet activity, which can be intervened through prophylactic anticoagulant treatment.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2021)
Article
Hematology
Ning Tang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2020)
Article
Medicine, General & Internal
Dominic Wichmann et al.
ANNALS OF INTERNAL MEDICINE
(2020)
Review
Hematology
Francesco Violi et al.
THROMBOSIS AND HAEMOSTASIS
(2020)
Article
Hematology
Bhanu Kanth Manne et al.
Article
Hematology
George Goshua et al.
LANCET HAEMATOLOGY
(2020)
Review
Hematology
Toshiaki Iba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2020)
Article
Hematology
Eugenio D. Hottz et al.
Article
Cardiac & Cardiovascular Systems
Younes Zaid et al.
CIRCULATION RESEARCH
(2020)
